Formulation Development Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation Development Forum
Analysis of crospovidone as a superdistingrant.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 50

The issue of peroxide contamination in crospovidone was recently underscored when the US Food and Drug Administration issued an advisory to manufacturers of drugs and dietary supplements to apprise them of a contaminated lot of crospovidone from a Chinese supplier (2). The peroxide level found by FDA in the lot was more than four times the maximum level of peroxide (400 ppm) allowed by global compendial monographs. FDA issued the advisory because it was "concerned that drug manufacturers using excipients containing high levels of peroxides will observe a loss of drug potency and the formation of excessive impurities during the product shelf life" (2). FDA advised manufacturers to use sound risk-management principles when working with a supplier of crospovidone to ensure the quality of the product.

In terms of functionality, commonly used superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate are effective at low concentration levels (2–5 w/w%) in tablet formulation by facilitating the rate and extent of tablet disintegration (3). Bee points out, however, that although these excipients are often comparable with respect to disintegration, there can be differences in dissolution. As a nonionic compound, crospovidone can be more effective with cationic active ingredients, an advantage compared with anionic disintegrants such as croscarmellose sodium and sodium starch glycolate, which would interact with the cationic actives and potentially retard dissolution. In one recent study, for example, ISP evaluated the respective effects of crospovidone, croscarmellose sodium, and sodium starch glycolate on the dissolution behavior of eight cationic drugs from a model direct-compression tablet formulation with 2% w/w superdisintegrant (3). Although no significant differences were observed in the disintegration times of the tablets, the study showed that actives formulated with crospovidone showed a more rapid dissolution rate than the same drugs formulated with other superdisintegrants for the cationic drugs studied, irrespective of the drug's aqueous solubility (3).

In a separate study, ISP evaluated the impact of the superdisintegrant on the dissolution of 13 poorly soluble drugs (4). Although no significant differences were observed in the disintegration times of the tablets, the study showed that actives formulated with crospovidone showed a more rapid dissolution rate than the same drugs formulated with other superdisintegrants for 12 of the 13 poorly soluble drugs studied.

Sources

1. Ph. Eur. 7.0 (Strasbourg, France), 1771–1773 (2011).

2. FDA, "Advisory to Drug and Dietary Supplement Manufacturers, Compounding Pharmacies and Distributors of Excipients and Dietary Ingredients—FDA Detects High Levels of Peroxide in Crospovidone" (Rockville, MD, Oct. 21, 2010).

3. J. Balasubramaniam et al., Dissolution Technol. 15 (2), 18–25 (2008).

4. J. Balasubramaniam and T. Bee, Pharm. Technol. 33 (4) supp. Excipient Performance for Solid Dosage Forms, s6–s14 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here